Haemonetics Corporation (NYSE:HAE) Position Increased by State of Alaska Department of Revenue

State of Alaska Department of Revenue boosted its stake in Haemonetics Corporation (NYSE:HAE) by 80.5% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 10,358 shares of the medical instruments supplier’s stock after buying an additional 4,618 shares during the period. State of Alaska Department of Revenue’s holdings in Haemonetics Corporation were worth $409,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of HAE. Kirr Marbach & Co. LLC IN boosted its stake in Haemonetics Corporation by 1.1% in the first quarter. Kirr Marbach & Co. LLC IN now owns 7,230 shares of the medical instruments supplier’s stock valued at $293,000 after buying an additional 80 shares in the last quarter. Municipal Employees Retirement System of Michigan boosted its stake in Haemonetics Corporation by 1.3% in the first quarter. Municipal Employees Retirement System of Michigan now owns 11,800 shares of the medical instruments supplier’s stock valued at $479,000 after buying an additional 150 shares during the period. Cardinal Capital Management boosted its stake in Haemonetics Corporation by 1.7% in the first quarter. Cardinal Capital Management now owns 11,773 shares of the medical instruments supplier’s stock valued at $478,000 after buying an additional 193 shares during the period. Envestnet Asset Management Inc. boosted its stake in Haemonetics Corporation by 0.9% in the first quarter. Envestnet Asset Management Inc. now owns 25,371 shares of the medical instruments supplier’s stock valued at $1,028,000 after buying an additional 225 shares during the period. Finally, Louisiana State Employees Retirement System boosted its stake in Haemonetics Corporation by 1.9% in the first quarter. Louisiana State Employees Retirement System now owns 21,200 shares of the medical instruments supplier’s stock valued at $860,000 after buying an additional 400 shares during the period.

Haemonetics Corporation (NYSE HAE) opened at 42.50 on Friday. The stock has a market cap of $2.24 billion, a PE ratio of 551.95 and a beta of 0.90. The company has a 50-day moving average of $40.24 and a 200-day moving average of $40.17. Haemonetics Corporation has a 12 month low of $32.76 and a 12 month high of $43.74.

Haemonetics Corporation (NYSE:HAE) last released its quarterly earnings results on Monday, August 7th. The medical instruments supplier reported $0.33 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.02. The company had revenue of $211 million for the quarter, compared to the consensus estimate of $211.29 million. Haemonetics Corporation had a net margin of 0.48% and a return on equity of 11.07%. Haemonetics Corporation’s revenue was up .5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.25 earnings per share. On average, equities analysts forecast that Haemonetics Corporation will post $1.61 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Haemonetics Corporation (NYSE:HAE) Position Increased by State of Alaska Department of Revenue” was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://transcriptdaily.com/2017/08/13/haemonetics-corporation-nysehae-position-raised-by-state-of-alaska-department-of-revenue-updated-updated.html.

Several analysts have recently weighed in on the stock. JMP Securities upgraded shares of Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $50.00 price objective on the stock in a research report on Thursday, July 13th. Zacks Investment Research cut shares of Haemonetics Corporation from a “hold” rating to a “sell” rating in a research report on Tuesday, May 9th. Jefferies Group LLC restated a “buy” rating and set a $42.00 price objective on shares of Haemonetics Corporation in a research report on Monday, May 8th. BidaskClub upgraded shares of Haemonetics Corporation from a “strong sell” rating to a “sell” rating in a research report on Tuesday, August 8th. Finally, TheStreet upgraded shares of Haemonetics Corporation from a “c” rating to a “b-” rating in a research report on Monday, August 7th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $40.63.

In related news, Director Ronald Merriman sold 17,471 shares of the company’s stock in a transaction on Monday, May 22nd. The shares were sold at an average price of $40.33, for a total transaction of $704,605.43. Following the sale, the director now owns 24,925 shares of the company’s stock, valued at $1,005,225.25. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 1.20% of the stock is owned by corporate insiders.

About Haemonetics Corporation

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Institutional Ownership by Quarter for Haemonetics Corporation (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply